Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sphingomod vs Gilenya in Healthy Volunteers
NCT04657744Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Aug 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fingolimod in multiple sclerosis (MS) (2 arms), sponsored by Genuine Research Center. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from time zero to last measurable concentration and 1 more. Started Aug 2020; status: completed.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04657744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04657744.